Chikungunya vaccine candidate safe and immunogenic in Phase III
Synopsis : Valneva’s single-shot chikungunya vaccine candidate, VLA1553, offered a very high level of seroprotection in all adults, including the elderly. The…
Synopsis : Valneva’s single-shot chikungunya vaccine candidate, VLA1553, offered a very high level of seroprotection in all adults, including the elderly. The…